Alcohol Withdrawal Scale AWS - Queensland Health

hallucinations Specify if: V = Visual t = tactile A = Auditory 0. lucid 1. infrequent, aware 2. Brief, persuadable 3. Frequent, distressed 4. No meaningful reality orientation 0. Fully oriented 1. Unsure of time 2. Unsure time, place 3. Unsure time, place, person 4. disorientated Total Blood pressure Pulse temperature respirations conscious ...

  Hallucinations

OBH-1A (PsyEC) Complete Prior Rev. 05/2017 to Admission ...

MENTAL CONDITION (ORIENTATION, MOOD, THOUGHT CONTENT, AFFECT, ANY HALLUCINATIONS OR DELUSIONS) PREVIOUS PSYCHIATRIC TREATMENT INPATIENT OUTPATIENT DATE OF TREATMENT PLACE, IF KNOWN IS PATIENT CURRENTLY: SUICIDAL HOMICIDAL VIOLENT I am of the opinion that the above person named is in need …

  Hallucinations

Drug Fact Sheet: Ketamine - DEA

Ketamine produces hallucinations. It distorts perceptions of sight and sound and makes the user feel disconnected and not in control. A “Special K” trip is touted as better than that of LSD or PCP because its hallucinatory effects are relatively short in duration, lasting approximately 30 to 60 minutes as opposed to several hours.

  Ketamine, Hallucinations

FACT SHEET Parkinson’s Dementia - Parkinson's Foundation

hallucinations . PD wwwparkinsonorg How many people with Parkinson’s develop dementia? The vast majority of people with Parkinson’s may experience some form of cognitive impairment over time. Though it is unique to each person, the development of dementia

  Foundations, Parkinson, Parkinson s foundation, Hallucinations

The ICD-10 Classification of Mental and Behavioural ...

(9) hallucinations with preserved orientation; (11) depersonalization; (12) derealization; (13) interference with personal functioning. C. At least one of the following signs must be present: (1) increased appetite; (2) dry mouth; (3) conjunctival injection; (4) tachycardia. F13.0 Acute intoxication due to use of sedatives or hypnotics A.

  Hallucinations

Ketamine Parenteral and Oral Dose Recommendations

Ketamine Parenteral and Oral Dose Recommendations • Pharmacology o Inhibits glutamate binding to NMDA-R receptor;activity at norepinephrine, serotonin, andmuscarinic cholinergic,kappa opioid,and voltage-sensitivecalciumchannel receptors • Pharmacokinetics o Lipophilic;Crosses blood brain barrier o Protein binding: 47% o Onsetof action: 1-5 min IV/IM, …